Trial · NCT00438854
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
NCT00438854, Phase 2, Completed, Massachusetts General Hospital; results first posted 2012-10-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Relapsed Chronic Lymphocytic Leukemia. Trials, record NCT00438854. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00438854
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Relapsed Chronic Lymphocytic Leukemia
- NCT number
- NCT00438854
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Dasatinib
- First posted
- 2007-02-22
- Last updated
- 2017-12-13
- Results first posted
- 2012-10-12
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Objective Response | 2 years | Overall objective response rate in terms of complete response, nodular partial response, and partial response to treatment. Objective response is when a biopsy shows. In general response is defined as the following (not complete criteria): Complete response (CR) requires all of the following for a period of at least 2 months: * Absence of lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Normal complete blood count Nodular partial response (nPR): Met the criteria for CR, but had residual bone marrow biopsy nodules as the only evidence of disease Partial response (PR): requires at least the following: * 50% decrease in peripheral blood lymphocyte count * 50% reduction in lymphadenopathy * 50% reduction in the size of the liver and/or spleen |
| Secondary | Complete Response Rate | 1 year | The number of participants with a 100% reduction in nodal mass. |
| Secondary | Median Time to Disease Progression | 1 year | The median time to disease progression, measured from the start of treatment. |
| Secondary | Median Overall Survival | 3 years | The median survival time, as measured from the start of treatment until death from any cause. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Objective Response | 2 years | participants who responded | NUMBER | |
| SECONDARY | Complete Response Rate | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Median Time to Disease Progression | 1 year | Months | MEDIAN | |
| SECONDARY | Median Overall Survival | 3 years | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Objective Response | Dasatinib Treatment | 3 | participants who responded | ||
| Complete Response Rate | Dasatinib Treatment | 0 | Participants | ||
| Median Time to Disease Progression | Dasatinib Treatment | 7.5 | Full Range 0.6 to 34.4 | Months | |
| Median Overall Survival | Dasatinib Treatment | 27 | Full Range 1.1 to 47.5 | Months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib Treatment | 15 | |
| Overall Study | COMPLETED | Dasatinib Treatment | 15 | |
| Overall Study | NOT COMPLETED | Dasatinib Treatment | 0 |
Source ClinicalTrials.gov
Adverse events17
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Dasatinib Treatment | 14 | 15 | |
| other | Neutrophil count decreased | Investigations | Dasatinib Treatment | 7 | 15 | |
| other | Platelet Count Decreased | Investigations | Dasatinib Treatment | 13 | 15 | |
| other | Nausea /vomiting | Gastrointestinal disorders | Dasatinib Treatment | 12 | 15 | |
| other | Heartburn | Gastrointestinal disorders | Dasatinib Treatment | 5 | 15 | |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib Treatment | 9 | 15 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib Treatment | 9 | 15 | |
| other | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Dasatinib Treatment | 4 | 15 | |
| other | Fatigue | General disorders | Dasatinib Treatment | 13 | 15 | |
| other | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Dasatinib Treatment | 2 | 15 |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib Treatment | 2 | 15 |
| Total, other adverse events | Dasatinib Treatment | 15 | 15 |
| Total, serious adverse events | Dasatinib Treatment | 10 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00438854
GET https://conductscience.org/api/trials/v1/NCT00438854/registered